Table 2.

Sex- and age-adjusted country-specific and total country-adjusted associations between IL-4Rα, IL-13, and COX-2 polymorphisms and glioblastoma

Gene (SNP) genotypeSweden
Southeast England
Denmark
Finland
Total
Cases/controls* (n = 110/436)OR (95% CI)Cases/controls* (n = 107/459)OR (95% CI)Cases/controls* (n = 66/602)OR (95% CI)Cases/controls* (n = 44/110)OR (95% CI)OR (95% CI)
IL-4Rα (rs1805015)
    TT65/2981.0063/3081.0046/4061.0036/751.001.00
    TC, CC43/1271.57 (1.01-2.45)43/1491.36 (0.87-2.12)19/1910.88 (0.50-1.55)8/350.46 (0.19-1.12)1.08 (0.70-1.66)
IL-4Rα (rs1801275)
    AA54/2531.0054/2751.0040/3651.0032/641.001.00
    AG, GG55/1651.56 (1.02-2.39)52/1801.45 (0.94. 2.24)26/2361.00 (0.59-1.68)12/450.54 (0.25-1.19)1.16 (0.79-1.69)
IL-13 (rs20541)
    GG75/2661.0070/3081.0042/3871.0020/421.001.00
    AG, AA35/1680.74 (0.47-1.16)37/1511.10 (0.70-1.72)24/2121.10 (0.62-1.79)24/670.66 (0.31-1.37)0.92 (0.71-1.12)
IL-13 (rs1800925)
    CC84/2861.0068/2941.0044/3501.0028/721.001.00
    CT, TT21/1310.56 (0.33-0.95)36/1460.99 (0.62-1.57)22/2490.70 (0.41-1.21)16/381.04 (0.49-2.22)0.78 (0.59-1.04)
COX-2 −765GC
    GG79/2981.0080/3291.0057/4431.0035/861.001.00
    GC, CC29/1140.95 (0.59-1.53)27/1280.85 (0.52-1.38)8/1550.40 (0.19-0.87)8/230.96 (0.38-2.42)0.81 (0.60-1.08)
  • NOTE: Data are results from population-based case-control studies conducted in Sweden, Southeast England, Denmark, and Finland (2000-2004).

  • * Number of cases and controls varies slightly depending on success of each SNP assay.

  • ORs estimated using two-stage random-effects meta-analysis (28).